Phase II study of safety and efficacy of intravenous LY2127399 in patients with rheumatoid arthritis treated with methotrexate

Trial Profile

Phase II study of safety and efficacy of intravenous LY2127399 in patients with rheumatoid arthritis treated with methotrexate

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2013

At a glance

  • Drugs Tabalumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 28 Jan 2013 Results published in the Arthritis and Rheumatism.
    • 16 Jun 2010 Results presented at 11th Annual Congress of the European League Against Rheumatism.
    • 20 Oct 2009 Results presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top